Q2. Who is the author of the manuscript?
Dr. Laurence Albiges has received consulting/advisory fees from BMS, Pfizer, Novartis, Sanofi, Amgen, Bristol-Myers Squibb, Bayer, and Cerulean; and research funding from Pfizer and Novartis.
Updated European Association of Urology Guidelines on Renal Cell Carcinoma : Immune Checkpoint Inhibition Is the New Backbone in First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma
Laurence Albiges,Thomas Powles,Michael Staehler,Karim Bensalah,Rachel H. Giles,Milan Hora,Markus A. Kuczyk,Thomas B. Lam,Börje Ljungberg,Lorenzo Marconi,Axel S. Merseburger,Alessandro Volpe,Yasmin Abu-Ghanem,Saeed Dabestani,Sergio Fernández-Pello,Fabian Hofmann,Teele Kuusk,Rana Tahbaz,Axel Bex,Axel Bex +19 more
TLDR
Pembrolizumab plus axitinib is a new standard of care for patients diagnosed with kidney cancer spread outside the kidney and who did not receive any prior treatment for their cancer (treatment naïve).About:
This article is published in European Urology.The article was published on 2019-08-01 and is currently open access. It has received 167 citations till now. The article focuses on the topics: Nivolumab & Clear cell renal cell carcinoma.read more
Figures
Table 3: New recommendations for treatment after immune checkpoint combination therapy in front-line 
Figure 1. Guidelines Recommendations for first-line therapy 
Figure 2. Guidelines Recommendations for later-line therapy 
Table 2: New recommendations for front-line treatment of metastatic clear-cell RCC
Citations
More filters
Journal ArticleDOI
Immunotherapy in Renal Cell Carcinoma: The Future Is Now
Antoine Deleuze,Judikaël Saout,Frédéric Dugay,Benoit Peyronnet,Romain Mathieu,Gregory Verhoest,Karim Bensalah,Laurence Crouzet,Brigitte Laguerre,Marc-Antoine Belaud-Rotureau,N. Rioux-Leclercq,Solène-Florence Kammerer-Jacquet +11 more
TL;DR: There is an urgent need to identify biomarkers in order to predict the efficacy of drugs and to better stratify patients to meet the unmet need of Renal cell carcinoma.
Journal ArticleDOI
Augmenting Anticancer Immunity Through Combined Targeting of Angiogenic and PD-1/PD-L1 Pathways: Challenges and Opportunities
TL;DR: The principle mechanisms of VEGF-mediated immunosuppression studied in preclinical models or as part of translational clinical studies are discussed and how these concepts and approaches can be further incorporated into clinical practice to improve immunotherapy outcomes for patients with cancer are discussed.
Journal ArticleDOI
Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma
TL;DR: The clinical data of single-agent TKIs and ICIs in mRCC and the rationale for the combination ICIs and TKis based on preclinical and clinical evidence are discussed.
Journal ArticleDOI
Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
Lewis Au,Lewis Au,Emine Hatipoglu,Emine Hatipoglu,Marc Robert de Massy,Kevin Litchfield,Gordon Beattie,Andrew Rowan,Desiree Schnidrig,Rachael Thompson,Fiona Byrne,Stuart Horswell,Nicos Fotiadis,Steve Hazell,David Nicol,Scott Shepherd,Scott Shepherd,Annika Fendler,Robert Mason,Lyra Del Rosario,Kim Edmonds,Karla Lingard,Sarah Sarker,Mary Mangwende,Eleanor Carlyle,Jan Attig,Kroopa Joshi,Imran Uddin,Pablo D. Becker,Mariana Werner Sunderland,Ayse Akarca,I Puccio,William Yang,Tom Lund,Kim Dhillon,Marcos Duran Vasquez,Ehsan Ghorani,Hang Xu,Charlotte Spencer,Jose Lopez,Anna Green,Ula Mahadeva,Elaine Borg,Miriam Mitchison,David Moore,David Moore,Ian Proctor,Mary Falzon,Lisa Pickering,Andrew Furness,James L. Reading,Roberto Salgado,Teresa Marafioti,Mariam Jamal-Hanjani,Christopher Abbosh,Kai-Keen Shiu,John Bridgewater,Daniel Hochhauser,Martin Forster,Siow Ming Lee,Tanya Ahmad,Dionysis Papadatos-Pastos,Sam M. Janes,Peter Van Loo,Katey S. S. Enfield,Nicholas McGranahan,Ariana Huebner,Stephan Beck,Peter J. Parker,Henning Walczak,Tariq Enver,Robert E. Hynds,Ron Sinclair,Chi-wah Lok,Zoe Rhodes,David A Moore,Reena Khiroya,Giorgia Trevisan,Peter Ellery,Mark Linch,Sebastian Brandner,Crispin T. Hiley,Selvaraju Veeriah,Maryam Razaq,Heather Shaw,Gert Attard,Mita Afroza Akther,Cristina Naceur-Lombardelli,Lizi Manzano,Maise Al-Bakir,Simranpreet Summan,Nnenna Kanu,Sophie Ward,Uzma Asghar,Emilia L. Lim,Faye Gishen,Adrian Tookman,Paddy Stone,Caroline Stirling,Nikki Hunter,Sarah Vaughan,Lavinia Spain,Haixi Yan,Ben Shum,Nadia Yousaf,Sanjay Popat,Olivia Curtis,Gordon Stamp,Antonia Toncheva,Emma Nye,Aida Murra,Justine Korteweg,Debra H. Josephs,Ashish Chandra,James Spicer,Ruby Stewart,Lara-Rose Iredale,Tina Mackay,Ben Deakin,Debra Enting,Sarah Rudman,Sharmistha Ghosh,Lena Karapagniotou,Elias Pintus,Andrew Tutt,Sarah Howlett,Vasiliki Michalarea,James D. Brenton,Carlos Caldas,Rebecca C. Fitzgerald,Merche Jimenez-Linan,Elena Provenzano,Alison Cluroe,Grant D. Stewart,Colin Watts,Richard J. Gilbertson,Ultan McDermott,Simon Tavaré,Emma Beddowes,Patricia Roxburgh,Andrew V. Biankin,Anthony J. Chalmers,Sioban Fraser,Karin A. Oien,Andrew C. Kidd,Kevin G. Blyth,Matt Krebs,Fiona H Blackhall,Yvonne Summers,Caroline Dive,Richard Marais,Fabio Gomes,Mat Carter,Jo Dransfield,John Le Quesne,Dean A. Fennell,Jacqui Shaw,Babu Naidu,S. Baijal,Bruce Tanchel,Gerald Langman,Andrew P. Robinson,Martin Collard,Peter Cockcroft,Charlotte Ferris,Hollie Bancroft,Amy Kerr,Gary Middleton,Joanne Webb,Salma Kadiri,Peter Colloby,Bernard Olisemeke,Rodelaine Wilson,Ian Tomlinson,Sanjay Jogai,Christian H. Ottensmeier,David G. Harrison,Massimo Loda,Adrienne M. Flanagan,Mairead McKenzie,Allan Hackshaw,Jonathan Ledermann,Kitty Chan,Abby Sharp,Laura Farrelly,Hayley Bridger,George Kassiotis,Benny Chain,James Larkin,Charles Swanton,Sergio A. Quezada,Samra Turajlic,Samra Turajlic,Ben Challacombe,Simon Chowdhury,William Drake,Archana Fernando,Karen Harrison-Phipps,Peter Hill,Catherine Horsfield,Tim O'Brien,Jonathon Olsburgh,Alexander Polson,Mary Varia,Hema Verma +204 more
TL;DR: ADAPTeR as mentioned in this paper is a prospective, phase II study of nivolumab (anti-PD-1) in 15 treatment-naive patients (115 multiregion tumor samples) with metastatic clear cell renal cell carcinoma (ccRCC) aiming to understand the mechanism underpinning therapeutic response.
Journal ArticleDOI
Safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma: a systematic review and meta-analysis
TL;DR: A systematic review and meta-analysis was performed with the aim to compare adverse events from immune-based combinations versus sunitinib monotherapy across four recent randomized controlled trials of front-line treatment for metastatic renal cell carcinoma, with particular attention to the ipilimumab plus nivolumab combination.
References
More filters
Journal ArticleDOI
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Nizar M. Tannir,David F. McDermott,Osvaldo Arén Frontera,Bohuslav Melichar,Toni K. Choueiri,Elizabeth R. Plimack,Philippe Barthélémy,Camillo Porta,Saby George,Thomas Powles,Frede Donskov,V. Neiman,V. Neiman,Christian Kollmannsberger,Pamela Salman,Howard Gurney,Robert E. Hawkins,Alain Ravaud,Marc-Oliver Grimm,Sergio Bracarda,Carlos H. Barrios,Yoshihiko Tomita,Daniel Castellano,Brian I. Rini,Allen C. Chen,Sabeen Mekan,M. Brent McHenry,Megan Wind-Rotolo,Justin Doan,Padmanee Sharma,Hans J. Hammers,Hans J. Hammers,Bernard Escudier +33 more
TL;DR: Overall survival and objective response rates were significantly higher with nivolumab plus ipilimumab than with sunitinib among intermediate‐ and poor‐risk patients with previously untreated advanced renal‐cell carcinoma.
Journal ArticleDOI
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini,Elizabeth R. Plimack,Viktor Stus,Rustem Gafanov,Robert E. Hawkins,Dmitry Nosov,Frédéric Pouliot,Boris Alekseev,Denis Soulières,Bohuslav Melichar,Ihor Vynnychenko,Anna Kryzhanivska,Igor Bondarenko,Sergio J Azevedo,Delphine Borchiellini,Cezary Szczylik,Maurice Markus,Raymond S. McDermott,Jens Bedke,Sophie Tartas,Yen-Hwa Chang,Satoshi Tamada,Qiong Shou,Rodolfo F. Perini,Mei Chen,Michael B. Atkins,Thomas Powles +26 more
TL;DR: Treatment with pembrolizumab plus axitinib resulted in significantly longer overall survival and progression‐free survival, as well as a higher objective response rate, than treatment with sunitin ib among patients with previously untreated advanced renal‐cell carcinoma.
Journal ArticleDOI
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer,Konstantin Penkov,John B. A. G. Haanen,Brian I. Rini,Laurence Albiges,Matthew T. Campbell,Balaji Venugopal,Christian Kollmannsberger,Sylvie Negrier,Motohide Uemura,Jae L. Lee,Aleksandr Vasiliev,Wilson H. Miller,Howard Gurney,Manuela Schmidinger,James Larkin,Michael B. Atkins,Jens Bedke,Boris Alekseev,Jing Wang,Mariangela Mariani,Paul B. Robbins,Aleksander Chudnovsky,Camilla Fowst,Subramanian Hariharan,Bo Huang,Alessandra di Pietro,Toni K. Choueiri +27 more
TL;DR: Progression‐free survival was significantly longer with avelumab plus axitinib than with sunit inib among patients who received these agents as first‐line treatment for advanced renal‐cell carcinoma.
Journal ArticleDOI
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2019 Update.
Börje Ljungberg,Laurance Albiges,Yasmin Abu-Ghanem,Karim Bensalah,Saeed Dabestani,Sergio Fernández-Pello,Rachel H. Giles,Fabian Hofmann,Milan Hora,Markus A. Kuczyk,Teele Kuusk,Thomas B. Lam,Lorenzo Marconi,Axel S. Merseburger,Thomas Powles,Michael Staehler,Rana Tahbaz,Alessandro Volpe,Axel Bex +18 more
TL;DR: These guidelines provide the most reliable contemporary evidence base for the management of RCC in 2019 and are thoroughly evaluated to establish international standards for the care of kidney cancer patients.
Journal ArticleDOI
Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
Toni K. Choueiri,Bernard Escudier,Thomas Powles,Paul N. Mainwaring,Brian I. Rini,Frede Donskov,Hans J. Hammers,Thomas E. Hutson,Jae-Lyun Lee,Katriina Peltola,Bruce J. Roth,Georg A. Bjarnason,Lajos Géczi,Bhumsuk Keam,Pablo Maroto,Daniel Y.C. Heng,Manuela Schmidinger,Philip W. Kantoff,Anne E. Borgman-Hagey,Colin Hessel,Christian Scheffold,Gisela Schwab,Nizar M. Tannir,Robert J. Motzer +23 more
TL;DR: Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.
Related Papers (5)
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Nizar M. Tannir,David F. McDermott,Osvaldo Arén Frontera,Bohuslav Melichar,Toni K. Choueiri,Elizabeth R. Plimack,Philippe Barthélémy,Camillo Porta,Saby George,Thomas Powles,Frede Donskov,V. Neiman,V. Neiman,Christian Kollmannsberger,Pamela Salman,Howard Gurney,Robert E. Hawkins,Alain Ravaud,Marc-Oliver Grimm,Sergio Bracarda,Carlos H. Barrios,Yoshihiko Tomita,Daniel Castellano,Brian I. Rini,Allen C. Chen,Sabeen Mekan,M. Brent McHenry,Megan Wind-Rotolo,Justin Doan,Padmanee Sharma,Hans J. Hammers,Hans J. Hammers,Bernard Escudier +33 more
Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Brian I. Rini,Elizabeth R. Plimack,Viktor Stus,Rustem Gafanov,Robert E. Hawkins,Dmitry Nosov,Frédéric Pouliot,Boris Alekseev,Denis Soulières,Bohuslav Melichar,Ihor Vynnychenko,Anna Kryzhanivska,Igor Bondarenko,Sergio J Azevedo,Delphine Borchiellini,Cezary Szczylik,Maurice Markus,Raymond S. McDermott,Jens Bedke,Sophie Tartas,Yen-Hwa Chang,Satoshi Tamada,Qiong Shou,Rodolfo F. Perini,Mei Chen,Michael B. Atkins,Thomas Powles +26 more
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Robert J. Motzer,Konstantin Penkov,John B. A. G. Haanen,Brian I. Rini,Laurence Albiges,Matthew T. Campbell,Balaji Venugopal,Christian Kollmannsberger,Sylvie Negrier,Motohide Uemura,Jae L. Lee,Aleksandr Vasiliev,Wilson H. Miller,Howard Gurney,Manuela Schmidinger,James Larkin,Michael B. Atkins,Jens Bedke,Boris Alekseev,Jing Wang,Mariangela Mariani,Paul B. Robbins,Aleksander Chudnovsky,Camilla Fowst,Subramanian Hariharan,Bo Huang,Alessandra di Pietro,Toni K. Choueiri +27 more
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Robert J. Motzer,Bernard Escudier,David F. McDermott,Saby George,Hans J. Hammers,Sandhya Srinivas,Scott S. Tykodi,Jeffrey A. Sosman,Giuseppe Procopio,Elizabeth R. Plimack,Daniel Castellano,Toni K. Choueiri,Howard Gurney,Frede Donskov,Petri Bono,John Wagstaff,Thomas Gauler,Takeshi Ueda,Yoshihiko Tomita,Fabio A.B. Schutz,Christian Kollmannsberger,James Larkin,Alain Ravaud,Jason S. Simon,Li-an Xu,Ian M. Waxman,Padmanee Sharma +26 more
Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study
Daniel Y.C. Heng,Wanling Xie,Meredith M. Regan,Mark Andrew Warren,Ali Reza Golshayan,Chakshu Sahi,Bernhard J. Eigl,J. Dean Ruether,Tina Cheng,Scott North,Peter Venner,Jennifer J. Knox,Kim N. Chi,Christian Kollmannsberger,David F. McDermott,William Oh,Michael B. Atkins,Ronald M. Bukowski,Brian I. Rini,Toni K. Choueiri +19 more